Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
12:00pm, Tuesday, 23'rd Jun 2020
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced
Cidara Therapeutics (NASDAQ:CDTX) Trading Up 9.9%
04:00am, Sunday, 14'th Jun 2020
Cidara Therapeutics Inc (NASDAQ:CDTX) shares rose 9.9% on Friday . The stock traded as high as $3.76 and last traded at $3.67, approximately 140,421 shares traded hands during mid-day trading. A decli
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
12:00pm, Thursday, 11'th Jun 2020
SAN DIEGO, June 11, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insiders Increased Their Holdings
01:33pm, Thursday, 04'th Jun 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE via COMTEX) --
SAN DIEGO and CAMBRIDGE, England, May 20, 2020 (GLOBE NEWSWIRE) -- Cidara...
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma
Cidara Therapeutics (CDTX) Reports Q1 Loss, Misses Revenue Estimates
10:05pm, Wednesday, 13'th May 2020
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -35.29% and -49.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
08:53pm, Wednesday, 13'th May 2020
SAN DIEGO, May 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced
What Makes Cidara Therapeutics (CDTX) a New Strong Buy Stock
04:00pm, Tuesday, 05'th May 2020
Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
01:09pm, Saturday, 02'nd May 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
SAN DIEGO, April 28, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
Analysts Offer Insights on Healthcare Companies: Interpace Diagnostics Group (IDXG) and Principia Biopharma (PRNB)
02:22pm, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Interpace Diagnostics Group (IDXG) and Principia Biopharma
Oppenheimer Keeps Their Buy Rating on Athenex (ATNX)
09:57pm, Wednesday, 22'nd Apr 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's shares
